142 related articles for article (PubMed ID: 16798701)
21. The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase.
Hornberger J; Farci P; Prati D; Zeuzem S; Green J; Patel KK
J Viral Hepat; 2006 Jun; 13(6):377-86. PubMed ID: 16842440
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response.
Gellad ZF; Muir AJ; McHutchison JG; Sievert W; Sharara AI; Brown KA; Flisiak R; Jacobson IM; Kershenobich D; Manns MP; Schulman KA; Reed SD
Value Health; 2012; 15(6):876-86. PubMed ID: 22999138
[TBL] [Abstract][Full Text] [Related]
23. A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels.
Gerkens S; Nechelput M; Annemans L; Peraux B; Beguin C; Horsmans Y
Acta Gastroenterol Belg; 2007; 70(2):177-87. PubMed ID: 17715631
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium.
Wong J; Nevens F
Acta Gastroenterol Belg; 2002; 65(2):110-11. PubMed ID: 12171045
[No Abstract] [Full Text] [Related]
25. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
Lo AO; Chan HL; Wong VW; Wong GL
J Gastroenterol Hepatol; 2017 May; 32(5):1071-1078. PubMed ID: 28449343
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of chronic hepatitis C treatment with thymosin alpha-1.
García-Contreras F; Nevárez-Sida A; Constantino-Casas P; Abud-Bastida F; Garduño-Espinosa J
Arch Med Res; 2006 Jul; 37(5):663-73. PubMed ID: 16740439
[TBL] [Abstract][Full Text] [Related]
28. A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C.
Sagmeister M; Wong JB; Mullhaupt B; Renner EL
Eur J Gastroenterol Hepatol; 2001 May; 13(5):483-8. PubMed ID: 11396525
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China.
Lu Y; Jin X; Duan CA; Chang F
PLoS One; 2018; 13(4):e0195117. PubMed ID: 29634736
[TBL] [Abstract][Full Text] [Related]
30. A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C.
Gerkens S; Nechelput M; Annemans L; Peraux B; Mouchart M; Beguin C; Horsmans Y
J Viral Hepat; 2007 Aug; 14(8):523-36. PubMed ID: 17650286
[TBL] [Abstract][Full Text] [Related]
31. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.
Grieve R; Roberts J; Wright M; Sweeting M; DeAngelis D; Rosenberg W; Bassendine M; Main J; Thomas H
Gut; 2006 Sep; 55(9):1332-8. PubMed ID: 15994216
[TBL] [Abstract][Full Text] [Related]
32. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
Arguedas M
Pharmacoeconomics; 2004; 22(7):477-8; author reply 478-9. PubMed ID: 15137884
[No Abstract] [Full Text] [Related]
33. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
Wong JB; Poynard T; Ling MH; Albrecht JK; Pauker SG
Am J Gastroenterol; 2000 Jun; 95(6):1524-30. PubMed ID: 10894590
[TBL] [Abstract][Full Text] [Related]
34. Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.
Visconti AJ; Doyle JS; Weir A; Shiell AM; Hellard ME
J Gastroenterol Hepatol; 2013 Apr; 28(4):707-16. PubMed ID: 23173753
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV.
Campos NG; Salomon JA; Servoss JC; Nunes DP; Samet JH; Freedberg KA; Goldie SJ
Am J Med; 2007 Mar; 120(3):272-9. PubMed ID: 17349451
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.
Cure S; Guerra I; Cammà C; Craxì A; Carosi G
J Med Econ; 2015; 18(9):678-90. PubMed ID: 25891129
[TBL] [Abstract][Full Text] [Related]
37. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients.
Annemans L; Warie H; Nechelput M; Peraux B
Acta Gastroenterol Belg; 2004; 67(1):1-8. PubMed ID: 15149079
[TBL] [Abstract][Full Text] [Related]
38. Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin HF; Cave CB; Waugh NR; Price A; Gabbay J
Int J Technol Assess Health Care; 2005; 21(1):47-54. PubMed ID: 15736514
[TBL] [Abstract][Full Text] [Related]
39. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.
Hassanein T; Cooksley G; Sulkowski M; Smith C; Marinos G; Lai MY; Pastore G; Trejo-Estrada R; Horta E Vale A; Wintfeld N; Green J
J Hepatol; 2004 Apr; 40(4):675-81. PubMed ID: 15030985
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis From the Brazilian Public Health System Perspective.
Borba HHL; Rochau U; Wiens A; Sroczynski G; Siebert U; Ferreira VL; Minowa E; Pontarolo R
Value Health Reg Issues; 2019 Dec; 20():95-102. PubMed ID: 31108456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]